Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Part 9 — The Future of Addiction Science: Where Research Is Heading Next
Mohamad-Ali Salloum, PharmD • April 13, 2026
Share
Addiction science is entering a new era. While early research focused largely on dopamine, reward pathways, and behavioral models, advances in neuroimaging, molecular biology, and data science are reshaping the field. Today’s emerging technologies and neuroscience-driven insights promise treatments that are more precise, personalized, and biologically informed.
This section examines key future directions in addiction research, based on emerging findings from 2024–2025.
1. High-Resolution Neuroimaging: Mapping Addiction Circuits in Unprecedented Detail 🧠🔬
Modern neuroimaging tools (fMRI, PET, EEG, MRS) are revealing how addiction impacts the brain on a level previously impossible to observe. A 2024 analysis of 409 clinical trial protocols found that most new addiction studies now incorporate neuroimaging as a core feature.
Most-used technologies include:
- functional MRI (268 studies)
- PET imaging (71 studies)
- EEG and structural MRI (50+ studies each)
These tools help researchers:
- identify biomarkers of craving, relapse risk, and treatment response
- study neurotransmitter receptor changes
- track executive function and salience network alterations
- distinguish individual neurobiological differences
In simple terms:
Future treatment will rely on brain scans that reveal your specific addiction circuitry — and which treatments will work best for you.
Future treatment will rely on brain scans that reveal your specific addiction circuitry — and which treatments will work best for you.
2. Biomarkers and Precision Medicine: Tailoring Treatment to the Individual 🧬✨
Biomarkers — measurable indicators of biological states — are becoming central to modern addiction science. A 2024 review highlights biomarker systems tied to:
- dopamine sensitivity
- glutamate–GABA balance
- stress-response pathways
- sex-based neurobiological differences
Sex differences, for example, significantly shape:
- craving intensity
- relapse risk
- reward sensitivity
- hormonal modulation of dopamine
The goal is to develop biomarker-specific treatments that account for these biological distinctions.
In simple terms:
Future addiction care won’t be one-size-fits-all — your biology will guide your treatment plan.
Future addiction care won’t be one-size-fits-all — your biology will guide your treatment plan.
3. Integrating Neurobiology With Psychotherapeutic Interventions 🧩🧠
A leading 2024 review emphasizes selecting psychotherapy based on neurobiological markers. Research increasingly shows:
- Prefrontal hypoactivity → stronger response to CBT
- Amygdala hyperactivity → better outcomes with EMDR and trauma therapy
- Interoceptive dysregulation → improved function with mindfulness-based therapies
This marks a shift toward matching therapy to each individual's brain profile.
In simple terms:
Therapists of the future will choose treatment based on how your brain responds to stress, reward, and craving.
Therapists of the future will choose treatment based on how your brain responds to stress, reward, and craving.
4. Neurotechnology-Based Treatments: A New Frontier ⚡🤖
Emerging technologies include:
Transcranial Magnetic Stimulation (TMS)
TMS targets prefrontal regions responsible for impulse control, reducing cravings — especially when combined with CBT.
EEG-Neurofeedback
Neurofeedback trains individuals to regulate neural patterns associated with stress and craving. 2025 research emphasizes its usefulness for improving emotional awareness and reward-processing circuits.
Digital & AI-Enhanced Therapies
New technologies aim to:
- track cravings in real time
- deliver immediate coping strategies
- personalize relapse-prevention plans
In simple terms:
Future technology will retrain the brain — and detect cravings before they become risky.
Future technology will retrain the brain — and detect cravings before they become risky.
5. Understanding Environmental and Social Complexity Through Data Science 📊🌍
2025 research highlights the need for large-scale, data-driven approaches to understand addiction. Machine learning, big data, and computational modeling are being used to analyze interactions between:
- environment
- genetics
- neurobiology
This helps researchers identify:
- who is most vulnerable to addiction
- which triggers are highest risk
- which treatments work for specific groups
In simple terms:
Data science will help explain why some people progress to addiction while others do not.
Data science will help explain why some people progress to addiction while others do not.
6. New Treatment Horizons: Psychedelics, GLP-1 Medications, and Beyond 🌈💊
Exciting new treatment areas include:
- Psychedelic-assisted therapy(psilocybin, ketamine) for treatment-resistant SUDs
- GLP-1 medications like semaglutide for reducing cravings through reward pathway modulation
- Stress-targeted therapies informed by epigenetic research
These approaches may offer solutions for individuals who do not respond to conventional treatments.
In simple terms:
New drugs — and psychedelic therapies — may revolutionize addiction treatment.
New drugs — and psychedelic therapies — may revolutionize addiction treatment.
✅ Quick Quiz: Test Your Understanding
Try answering these questions before reviewing the text:
- What role will neuroimaging biomarkers play in future addiction treatment?
- How might sex-specific biomarkers shape personalized treatment strategies?
- Why will future therapy types likely be matched to brain activity patterns?
- Name one neurotechnology-based treatment that may become widespread.
- How could data science improve our understanding of addiction vulnerability?
References:
- Darcq E, Kieffer BL. Neuroscience and addiction research: current advances and perspectives. J Neural Transm. 2024;131:405–408. 6
- Lomas C. Neurobiology, psychotherapeutic interventions, and emerging therapies in addiction: a systematic review. J Addict Dis. 2024. 3
- Ekhtiari H, et al. Neuroimaging biomarkers in addiction. medRxiv. 2024. 1
- Unterrainer HF. Addiction, attachment, and the brain. Front Hum Neurosci. 2025. 4
- Psychology Today. Top 2025 Addiction Research Articles. 2025. 9
- Sardari M, et al. Neuronal biomarkers as therapeutic targets; sex differences. Prog NeuroPsychopharmacol Biol Psychiatry. 2024. 2
- Aspira CE. Latest Trends in Addiction Treatment and Recovery 2025. 2025. 5
- Westlake Consultation Center. Innovations in Addiction Treatment 2025. 2025. 8
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
Explore the difference between Sensitivity and Specificity
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to Distinguish Correlation from Causation in Orthopaedic Research. J Arthroplasty. 2022;38(4):634‑637. [pmc.ncbi.nlm.nih.gov] Association of Health Care Journalists. Correlation vs. Causation. [healthjournalism.org] Rush J, Ajami M, Look K, Margolis A. Statistics Review Part 10: Causality and Confounding. J Pharm Soc Wis. [jpswi.org] Biostat Prime. Correlation vs Causation: Meaning, Differences & Examples. [biostatprime.com] Koopmans E, Schiller C. Understanding Causation in Healthcare: An Introduction to Critical Realism. Qual Health Res. 2022;32(8–9):1207–1214. [pmc.ncbi.nlm.nih.gov]
References: Very Big Brain. Somatic Memories: How Physical Sensations Trigger Past Memories and Emotions . 2023 Nov 26. [verybigbrain.com] Misattribution of arousal. Wikipedia . 2026. [en.wikipedia.org] Zimbardo P. The Misattribution of Arousal Study (Dutton & Aron) . 2026. [zimbardo.com] Higgins L. Why You Feel Anxious After Drinking Coffee . TIME. 2025 Nov 11. [time.com] Double KS. Metacognitive ability is associated with reduced emotion suppression . Scientific Reports. 2026 Jan 28. [nature.com] Merkebu J et al. What is metacognitive reflection? Front Educ. 2023 Apr 5. [researchgate.net] Meyers S et al. Cognitive Reappraisal is More Effective for Regulating Emotions than Moods . Affective Science. 2025 Jun 6. [link.springer.com]
Are they the same?
A Practical Guide for the Public.
Did you know that your emotions are just suggestions?
Short-form videos like Reels and TikTok rapidly trigger dopamine, stress, and attention circuits—discover how they impact your brain, mood, and focus, plus practical tips to restore balance.